PK Study With Pantoprazole in Obese Children and Adolescents



Status:Completed
Conditions:Gastroesophageal Reflux Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:6 - 17
Updated:6/28/2018
Start Date:June 4, 2014
End Date:September 13, 2015

Use our guide to learn which trials are right for you!

The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children and Adolescents

Multicenter, comparative single-dose pharmacokinetic (PK) study

Evaluate the pharmacokinetics of pantoprazole in obese children and adolescents with
gastroesophageal reflux disease (GERD) following administration of an oral dose of
pantoprazole.

Inclusion Criteria:

1. Participant is between 6 and 17 (inclusive) years of age at the time of consent

2. BMI ≥95th percentile

3. Diagnosis of GERD established prior to 7 days before receipt of study drug dose
defined as 1 or more of the following:

1. clinical symptoms consistent with GERD as determined by the investigator

2. a diagnosis of erosive esophagitis by endoscopy

3. esophageal biopsy with histopathology consistent with reflux esophagitis

4. abnormal pH-metry consistent with reflux esophagitis

5. other test result consistent with GERD

4. Written informed consent from the parent or legally authorized representative/guardian
and participant assent per local IRB recommendation of age-appropriate consent and
assent requirements

Exclusion Criteria:

1. Use of pantoprazole, lansoprazole, omeprazole, esomeprazole or rabeprazole within 48
hours prior to dose of study drug

2. Use of fluoxetine, fluvoxamine, ketoconazole, ticlopidine, felbamate, topiramate,
valproic acid, phenobarbital, carbamazepine, erythromycin, clarithromycin, grapefruit
juice, verapamil, diltiazem, cimetidine, St. John's Wort, rifampin, rifapentine within
seven days prior to dose of study drug

3. Consumption of food after midnight on the day of the baseline visit

4. Symptomatic asthma

5. Type I diabetes

6. History of adverse reaction to PPI

7. Impaired hepatic activity as defined as any of the following: AST ≥150 IU/L, ALT ≥150
IU/L, total bilirubin ≥2.0 mg/dl, or alkaline phosphatase ≥600 IU/L

8. Serum creatinine ≥2.0 mg/dL

9. For females of childbearing potential, a positive pregnancy test result

10. Known infection with hepatitis B, C, or HIV

11. Any other condition that, in the opinion of the principal investigator, makes
participation unadvised or unsafe.
We found this trial at
4
sites
Little Rock, Arkansas 72202
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
2401 Gillham Rd
Kansas City, Missouri 64108
(816) 234-3000
Children's Mercy Hospital Children's Mercy Hospitals and Clinics continues redefining pediatric medicine throughout the Midwest...
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
201 Presidents Circle
Salt Lake City, Utah 84108
801) 581-7200
University of Utah Research is a major component in the life of the U benefiting...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
1001 E 5th St
Greenville, North Carolina 27858
(252) 328-6131
East Carolina University Whether it's meeting the demand for more teachers and healthcare professionals or...
?
mi
from
Greenville, NC
Click here to add this to my saved trials